je.st
news
Zacks Investment Research Downgrades Celsion Co. (CLSN) to Sell
2016-04-05 02:28:40| Biotech - Topix.net
According to Zacks, "Celsion is dedicated to the development and commercialization of oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat activated drug delivery systems. Celsion has research, license or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, North Shore Long Island Jewish Health System.
Tags: research
sell
investment
downgrades
Category:Biotechnology and Pharmaceuticals